CD8A and acute myeloid leukemia: While EREs are perfect candidates for generating immunogenic MAPs following hypomethylating agents treatment, there is a lack of robust evidence to support that hypomethylating agents enhance their MAP presentation (and subsequent CD8+ T-cell responses) in AML.